Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Presentation

Poster: Preclinical Development of ST-503: an Investigational Adeno-associated Viral Vector Delivered Zinc Finger Repressor Novel Epigenetic Therapy for Idiopathic Small Fiber Neuropathy

Download PDF